Pharming Group NV

Netherlands Country flag Netherlands
Sector: Biotechnology
Ticker: PHARM
ISIN: NL0010391025
Factsheet Factsheet

Market multiple valuation of Pharming Group NV ( PHARM | NLD)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of Pharming Group NV is significantly higher than the median of its peer group: around 17.00. The company valuation of Pharming Group NV according to these metrics is way above the market valuation of its peer group.
The P/Earnings NTM ratio of Pharming Group NV is significantly lower than the average of its sector (Biotechnology): -2.19. The company valuation of Pharming Group NV according to these metrics is way below the market valuation of its sector.
The P/Earnings NTM ratio of Pharming Group NV is significantly higher than its historical 5-year average: 40.0. The (current) company valuation of Pharming Group NV is therefore way above its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2024P/E NTM
Pharming Group NVFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Biotechnology-2.14-2.18-2.19
AEX 2517.3014.0913.63
Netherlands8.6211.0811.24
More...
Beta (Ref: AEX 25)
Levered betaUnlevered beta
1-Year0.740.78
2-Year0.790.84
3-Year0.770.82
More...
Stock Perf excl. Dividends (in EUR)
PHARMAEX 25Rel. Perf.
Year-to-Date-14.2%11.7%-25.8%
1-Week0.4%1.0%-0.5%
1-Month-12.0%-0.3%-11.7%
1-Year-12.6%18.1%-30.6%
3-Year-16.6%24.2%-40.8%
5-Year7.9%55.1%-47.2%
More...
International Peers - Pharming Group NV
Company NameCtryMarket
Cap.
last (mUSD)
Pharming Group NVNLD638
International Peers Median1.60
Pharvaris NVNLD1 266
BELLUS Health Inc.CANN/A
Bavarian Nordic A/SDNK1 701
Biotest AGDEU1 501
Lyell Immunopharma, Inc...USA602
GPRV Analysis
Pharming Group NV
Intl. Peers
U.S Patents No. 7,882,001 & 8,082,201
More...
Net Sales Chart
More...
Quotes Chart

1-Year Rebased Stock Chart

  • Pharming Group NV
  • AEX 25
More...

Did you know ?

On the Infront Analytics platform, there are two ways to identify the listed peers which most closely resemble a private firm:
- with Peer Tracker if you already know a listed peer.
Peer Tracker is a patented technology tool for building peer groups using industry classifications. The degree of similarity between two companies is calculated comparing their sector footprints and measured using comparability scores.
- with Market Screener if you have no listed peer in mind.
Market Screener is a dedicated interface for screening companies using multiple criteria, identifying peers, searching for comparable companies in a specific business sector.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).